Skip to content
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • newsletter
  • Investors 
  • Careers
  • Contact
  • X
  • en_US
  • ja
  • en_US
  • ja
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation

    Pharmacokinetics & distribution

    PK & Distribution
    Bioanalysis
    Vectors & gene therapy distribution
    Biomarker studies

    Behavioral tests

    Tinnitus detection
    GPIAS & PPI
    Hyperacusis

    Delivery capabilities

    Transtympanic
    Intracochlear
    Systemic

    Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    Screening / dose selection for ototoxicity or otoprotection

    In vitro on Otic cell line
    Ex vivo on Cochlear explants
    In vivo in Zebrafish

    Formulation

    Formulation for otic delivery

    Animal models

    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other disease & transgenic models
    Rodent & large species

    Our missions

    In vivo studies

    Auditory efficacy studies
    Auditory tolerance & safety studies
    Auditory phenotyping studies
    GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    Modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    Electrophysiology & electroacoustic

    ABR
    DPOAE
    Wave I to V analysis
    CAP & unicellular electrophysiology

    Ear assessment

    Otoscopy
    Tympanometry
    Gross middle ear assessment

    Pathology & histopathology

    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    Molecular biology & biochemistry

    Biochemistry
    Molecular biology

    OUR MISSIONS

    IN VITRO / EX VIVO / IN VIVO EFFICACY

    FORMULATION & DISTRIBUTION

    OTOTOXICITY

    CLINICAL AUDITORY BIOMARKER

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgeries

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Middle ear
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Auditory biomarkers in clinical trials

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Transtympanic
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Clinical biomarker studies

  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
Fichier 2
Read more about the article Cilcare appoints Camille Rochmann as Evidence, Value & Access Senior Manager
Camille Rochmann

Cilcare appoints Camille Rochmann as Evidence, Value & Access Senior Manager

  • Post author:marie.peytavy
  • Post published:4 September 2025
  • Post category:Appointment

Montpellier, France, September 4th 2025 : Cilcare, a biotechnology company specializing in auditory sciences, is pleased to announce the appointment of Camille Rochmann, PharmD, as Evidence, Value & Access Senior…

Continue ReadingCilcare appoints Camille Rochmann as Evidence, Value & Access Senior Manager
Read more about the article Cilcare appoints Naimi Missoum as Chief Medical Officer
Naimi Missoum

Cilcare appoints Naimi Missoum as Chief Medical Officer

  • Post author:marie.peytavy
  • Post published:23 May 2024
  • Post category:Appointment

Montpellier - France – May 23rd, 2024 – Cilcare, a clinical-stage biotechnology company specialized in auditory sciences and research and development of novel therapies for the inner ear and associated…

Continue ReadingCilcare appoints Naimi Missoum as Chief Medical Officer
Linkedin-in X
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
cilcare
MONTPELLIER • BOSTON • PARIS

info@cilcare.com

Intra-Community VAT: FR00803146125

cilcare | Mentions légales | Conception : Malice | Développement : Linov ©2025
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
About cilcare
Who we are
Our team
Scientific advisors
Hearing loss & Aging connection
External Innovation

Pharmacokinetics & distribution

PK & Distribution
Bioanalysis
Vectors & gene therapy distribution
Biomarker studies

Behavioral tests

Tinnitus detection
GPIAS & PPI
Hyperacusis

Delivery capabilities

Transtympanic
Intracochlear
Systemic

Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

Screening / dose selection for ototoxicity or otoprotection

In vitro on Otic cell line
Ex vivo on Cochlear explants
In vivo in Zebrafish

Formulation

Formulation for otic delivery

Animal models

Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other disease & transgenic models
Rodent & large species

Our missions

In vivo studies

Auditory efficacy studies
Auditory tolerance & safety studies
Auditory phenotyping studies
GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

Modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

Electrophysiology & electroacoustic

ABR
DPOAE
Wave I to V analysis
CAP & unicellular electrophysiology

Ear assessment

Otoscopy
Tympanometry
Gross middle ear assessment

Pathology & histopathology

Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

Molecular biology & biochemistry

Biochemistry
Molecular biology

OUR MISSIONS

IN VITRO / EX VIVO / IN VIVO EFFICACY

FORMULATION & DISTRIBUTION

OTOTOXICITY

CLINICAL AUDITORY BIOMARKER

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgeries

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Middle ear
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Auditory biomarkers in clinical trials

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Transtympanic
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

Therapeutics
Our missions
Our pipeline
Cochlear synaptopathy
Our clinical studies
Auditory Analytics
  • en_US
  • ja
  • en_US
  • ja
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok